Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. on behalf of investors who acquired StubHub securities during the specified Class Period, alleging undisclosed issues related to the company's IPO [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague on behalf of investors who purchased StubHub securities from September 14, 2025, to November 24, 2025, including shares from the September 2025 IPO [1][2]. - Investors have until January 23, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations Against StubHub - The complaint claims that StubHub's IPO Registration Statement failed to disclose significant changes in the timing of payments to vendors, which adversely affected the company's free cash flow [3].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Performance - Skye Bioscience's lead product candidate, nimacimab, reportedly did not meet the primary weight-loss endpoint in a Phase 2a study, leading to a significant drop in share price [4]. - Following the announcement of the study results, Skye's share price fell by 60%, decreasing from $4.75 to $1.90 per share [4]. Group 3: Company Background - Skye Bioscience is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) on behalf of investors who acquired its securities during the specified Class Period, alleging misleading information regarding loan delinquencies [1][3]. Group 1: Lawsuit Details - The lawsuit claims that during the Class Period from July 25, 2025, to August 14, 2025, Sallie Mae misled investors about the state of its loan delinquencies, asserting that increases were typical seasonal patterns while downplaying the severity of the situation [3]. - Investors became aware of the true condition of Sallie Mae's loan portfolio following a report from TD Cowen on August 14, 2025, which indicated a 49-basis-point month-over-month increase in July delinquencies, surpassing seasonal norms [4]. Group 2: Stock Impact - Following the revelation of the actual delinquency rates, Sallie Mae's stock price fell by $2.67 per share, representing an 8.09% decline, closing at $30.32 on August 15, 2025 [4]. Group 3: Investor Actions - Investors who purchased Sallie Mae securities during the Class Period have until February 17, 2026, to seek appointment as lead plaintiff representatives of the class [2].

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc on behalf of investors who acquired Klarna securities during the specified class period, alleging that the company failed to disclose material financial risks in its IPO documents [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Klarna underestimated the likelihood of rising loss reserves shortly after its IPO, which is linked to the high-risk profiles of its customers [3]. - Investors who purchased Klarna securities during the class period have until February 20, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Financial Impact - Following a report on November 18, 2025, that Klarna had set aside greater provisions for credit losses than anticipated, the company's share price declined by 21% from the IPO price of $40 to $31.31 [4].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for allegedly misrepresenting its product performance and integrity, leading to investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Stride securities from October 22, 2024, to October 28, 2025 [1][2]. - Investors have until January 12, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Stride - The complaint alleges that Stride overstated enrollment figures and reduced staff costs beyond legal limits [3]. - Stride is accused of failing to meet compliance standards and losing key enrollments while assuring investors of its commitment to personalized learning [3]. - The company's stock price declined when these issues became known, resulting in losses for investors [3]. Group 3: Company Background - Stride, Inc. is an education technology company based in Reston, Virginia, providing digital learning programs and instructional support to public and private schools [2].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased its securities during the specified Class Period, alleging misleading statements regarding the company's business and operations [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Telix - Defendants are accused of making false or misleading statements and failing to disclose that Telix overstated its progress with prostate cancer therapeutic candidates [3]. - The company allegedly exaggerated the quality of its supply chain and partners, leading to misleading statements about its business and prospects [3]. - The complaint claims that when the true state of Telix's business was revealed, investors experienced significant financial losses [3].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased its securities during the specified class period, alleging misleading statements regarding the company's business and operations [1][3]. Group 1: Lawsuit Details - The lawsuit targets Telix Pharmaceuticals Ltd. for allegedly making false or misleading statements about its prostate cancer therapeutic candidates, supply chain quality, and overall business prospects [3]. - Investors who bought Telix securities between February 21, 2025, and August 28, 2025, are eligible to seek appointment as lead plaintiff representatives by January 9, 2026 [2]. Group 2: Company Background - Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, focusing on the development of radiopharmaceuticals for cancer treatment [2]. - Berger Montague, the law firm representing the plaintiffs, has a strong track record in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [4].

Core Viewpoint - A class action lawsuit has been filed against Six Flags Entertainment Corp. by Berger Montague PC on behalf of investors who purchased shares during the Class Period from July 1, 2024, to November 5, 2025, related to the merger with Cedar Fair L.P. [1][3] Group 1: Lawsuit Details - The lawsuit alleges that the merger registration statement did not accurately reflect Six Flags' operational and capital needs, claiming that the company had suffered from years of underinvestment despite public claims of major investments [3] - The complaint states that undisclosed capital requirements were inconsistent with the rationale provided for the merger [3] Group 2: Stock Performance - Following the merger closure on July 1, 2024, Six Flags' stock initially traded above $55 per share but subsequently fell to as low as $20, representing a decline of nearly 64% [4]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making misleading statements and failing to disclose material adverse facts regarding its business performance during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit represents investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint claims that Integer overstated its competitive position and did not adequately disclose sales deterioration in its electrophysiology devices [3]. - The lawsuit also alleges that the company mischaracterized its growth drivers [3]. Group 3: Impact on Stock Price - Following the disclosure of reduced sales guidance and an expected sales decline on October 23, 2025, Integer's stock price fell by $35.22 per share, a decline of over 32% in one trading day [3].

Core Viewpoint - A class action lawsuit has been filed against Six Flags Entertainment Corp. on behalf of investors who acquired shares during the specified Class Period, alleging that the merger with Cedar Fair L.P. was misrepresented in terms of the company's financial and operational health [1][3]. Group 1: Lawsuit Details - The lawsuit claims that the registration statement and prospectus related to the merger did not accurately reflect Six Flags' financial and operational condition, highlighting a history of underinvestment in its parks [3]. - Investors who purchased Six Flags securities during the Class Period have until January 5, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Stock Performance - On the merger's closing date, July 1, 2024, Six Flags stock was trading above $55 per share, but it subsequently fell to as low as $20, representing a decline of nearly 64% [4].